Disc Medicine, Inc. (NASDAQ:IRON) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 275.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 61,017 shares of the company's stock after acquiring an additional 44,762 shares during the quarter. JPMorgan Chase & Co. owned 0.21% of Disc Medicine worth $3,868,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new position in shares of Disc Medicine during the fourth quarter valued at approximately $235,000. Teacher Retirement System of Texas lifted its stake in shares of Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after acquiring an additional 396 shares during the last quarter. Virtu Financial LLC purchased a new position in Disc Medicine during the 4th quarter valued at $309,000. China Universal Asset Management Co. Ltd. grew its position in Disc Medicine by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock valued at $400,000 after acquiring an additional 593 shares during the last quarter. Finally, Bleakley Financial Group LLC purchased a new stake in Disc Medicine in the fourth quarter worth $486,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IRON has been the topic of a number of research analyst reports. TD Cowen started coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating on the stock. Scotiabank upped their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. Morgan Stanley reaffirmed an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. Cantor Fitzgerald boosted their price target on Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. Finally, Stifel Nicolaus raised their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, January 24th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $93.80.

Insider Buying and Selling at Disc Medicine

In other news, insider Rahul Khara sold 7,500 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $55.54, for a total value of $416,550.00. Following the completion of the sale, the insider now owns 14,035 shares of the company's stock, valued at $779,503.90. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John D. Quisel sold 5,574 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $304,228.92. Following the transaction, the chief executive officer now owns 154,828 shares in the company, valued at approximately $8,450,512.24. This trade represents a 3.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 361,690 shares of company stock worth $19,648,094 over the last three months. Corporate insiders own 4.24% of the company's stock.

Disc Medicine Trading Up 2.5 %

Shares of IRON traded up $1.15 during trading hours on Thursday, hitting $46.30. The company had a trading volume of 128,564 shares, compared to its average volume of 345,479. Disc Medicine, Inc. has a one year low of $25.64 and a one year high of $68.73. The company's fifty day moving average price is $48.89 and its two-hundred day moving average price is $55.05. The company has a market capitalization of $1.60 billion, a PE ratio of -11.63 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.08. Analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.